Table 1.
Characteristics and variables considered in initial cluster analysis
| Characteristic/variable: class | Characteristic/variable: specific |
|---|---|
| Spirometry | • Post-bronchodilator FEV1 L • Post-bronchodilator FEV1 % predicted • FEV1% reversibility • Post-bronchodilator FEV1/FVC ratio • Post-bronchodilator FVC% predicted |
| Demographics | • Age (years) • Sex • BMI (kg/m2) • Smoking (current/former) • Smoking pack-years |
| Race | • African American/African heritage • American Indian/Alaska Native • Asian • Mixed • White |
| COPD history | • Duration of COPD (years) • COPD type (chronic bronchitis and/or emphysema) |
| History of exacerbation (past year) | • ≤1 versus ≥2 requiring oral corticosteroids and/or antibiotics • ≤1 versus ≥2 requiring hospitalization 0, 1, 2, >2 or more |
| Medical history | • Targeted medical conditions* • Vaccination for influenza (yes versus no) • Vaccination for pneumonia (yes versus no) |
| Medications at baseline/initiated prior to randomization | • ATC classification** |
| Laboratory investigations | • Blood urea nitrogen • Eosinophils • Hemoglobin • Lymphocytes • Neutrophils • Red blood cells • White blood cells |
| Randomized treatment | • VI 25 μg • FF/VI treatment (50/25 μg, 100/25 μg, 200/25 μg) |
Notes:
Targeted medical conditions: cardiovascular history/risk, vascular disorders, metabolism disorders, history of pneumonia, cardiac disorders, eye disorders, arrhythmia;
medications were coded based on the ATC of interest. Some medications have more than one indication and were categorized in more than one therapeutic class (eg, aspirin for pain relief versus cardiovascular disease prevention). Because the reasons for taking the medications were not collected systematically, the classification was based on the ATC classes and not on the underlying indication for an individual patient. It is possible that some medications were counted in more than one ATC category. Medication classes included in the analysis included: antihistamines, antihypertensives, antithrombotics, diuretics, diabetes medications, psychoanaleptics, psycholeptics, agents acting on the renin–angiotensin system (eg, angiotensin-converting enzyme inhibitors, angiotensin II agonists), antihemorrhagics, antianemic preparations, beta-blockers, cardiac therapies, calcium channel blockers, lipid-modifying agents, anti-inflammatory and antirheumatic products, medications for bone diseases (including muscle pain), antihemorrhagics, and vasodilators.
Abbreviations: ATC, Anatomic Therapeutic Category; COPD, chronic obstructive pulmonary disease; BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FF/VI, fluticasone furoate/vilanterol; VI, vilanterol.